JP7601635B2 - 抗ｐｄ－１抗体とその作製及び使用方法 - Google Patents

抗ｐｄ－１抗体とその作製及び使用方法 Download PDF

Info

Publication number
JP7601635B2
JP7601635B2 JP2020520425A JP2020520425A JP7601635B2 JP 7601635 B2 JP7601635 B2 JP 7601635B2 JP 2020520425 A JP2020520425 A JP 2020520425A JP 2020520425 A JP2020520425 A JP 2020520425A JP 7601635 B2 JP7601635 B2 JP 7601635B2
Authority
JP
Japan
Prior art keywords
seq
antigen
acid sequence
antibody
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020520425A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020529862A5 (https=
JPWO2019005635A5 (https=
JP2020529862A (ja
Inventor
ブライアン コヴァセヴィチ，
ドン シア，
アン イー． ジェンセン，
ジョナサン ケー． ファレン，
ブレア レンショー，
ジェフリー ビー． アダモ，
フィル タン，
ゼレン ガオ，
イ ツー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Systimmune Inc
Original Assignee
Systimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Systimmune Inc filed Critical Systimmune Inc
Publication of JP2020529862A publication Critical patent/JP2020529862A/ja
Publication of JP2020529862A5 publication Critical patent/JP2020529862A5/ja
Publication of JPWO2019005635A5 publication Critical patent/JPWO2019005635A5/ja
Priority to JP2023061568A priority Critical patent/JP7490109B2/ja
Application granted granted Critical
Publication of JP7601635B2 publication Critical patent/JP7601635B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020520425A 2017-06-25 2018-06-22 抗ｐｄ－１抗体とその作製及び使用方法 Active JP7601635B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023061568A JP7490109B2 (ja) 2017-06-25 2023-04-05 抗ｐｄ－１抗体とその作製及び使用方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201762524554P 2017-06-25 2017-06-25
US201762524558P 2017-06-25 2017-06-25
US201762524557P 2017-06-25 2017-06-25
US201762524553P 2017-06-25 2017-06-25
US62/524,554 2017-06-25
US62/524,558 2017-06-25
US62/524,557 2017-06-25
US62/524,553 2017-06-25
US201762545603P 2017-08-15 2017-08-15
US62/545,603 2017-08-15
PCT/US2018/039147 WO2019005635A2 (en) 2017-06-25 2018-06-22 ANTI-PD-1 ANTIBODIES AND METHODS OF PREPARATION AND USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023061568A Division JP7490109B2 (ja) 2017-06-25 2023-04-05 抗ｐｄ－１抗体とその作製及び使用方法

Publications (4)

Publication Number Publication Date
JP2020529862A JP2020529862A (ja) 2020-10-15
JP2020529862A5 JP2020529862A5 (https=) 2022-01-17
JPWO2019005635A5 JPWO2019005635A5 (https=) 2022-01-17
JP7601635B2 true JP7601635B2 (ja) 2024-12-17

Family

ID=64742653

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020520425A Active JP7601635B2 (ja) 2017-06-25 2018-06-22 抗ｐｄ－１抗体とその作製及び使用方法
JP2023061568A Active JP7490109B2 (ja) 2017-06-25 2023-04-05 抗ｐｄ－１抗体とその作製及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023061568A Active JP7490109B2 (ja) 2017-06-25 2023-04-05 抗ｐｄ－１抗体とその作製及び使用方法

Country Status (5)

Country Link
US (1) US11466084B2 (https=)
EP (1) EP3645740A4 (https=)
JP (2) JP7601635B2 (https=)
CN (1) CN110799537B (https=)
WO (1) WO2019005635A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021006199A1 (ja) 2019-07-05 2021-01-14 小野薬品工業株式会社 Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療
EP4011918A4 (en) 2019-08-08 2023-08-23 ONO Pharmaceutical Co., Ltd. DUAL SPECIFIC PROTEIN
CN116209466A (zh) * 2020-08-27 2023-06-02 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗鼻咽癌中的用途
EP4293046A4 (en) * 2021-02-10 2025-03-05 Shanghai Jemincare Pharmaceuticals Co., Ltd. Anti-pd-1 antibody and use thereof
CN116687933B (zh) * 2022-02-28 2025-10-31 中国科学院上海药物研究所 甲氨蝶呤及其药物组合物在肿瘤免疫治疗中的用途
WO2024160721A1 (en) 2023-01-30 2024-08-08 Kymab Limited Antibodies
CN119775428B (zh) * 2024-12-12 2025-08-05 广东沃博生物医药科技有限公司 一种免疫细胞的制备方法及其在治疗疾病中的用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010530753A (ja) 2007-06-18 2010-09-16 エン． フェー． オルガノン ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
WO2016014688A2 (en) 2014-07-22 2016-01-28 Junzhuan Qiu Anti-pd-1 antibodies
WO2017019846A1 (en) 2015-07-30 2017-02-02 Macrogenics, Inc. Pd-1-binding molecules and methods use thereof
JP2017506067A (ja) 2014-01-24 2017-03-02 デイナ ファーバー キャンサー インスティチュート，イ Ｐｄ−１に対する抗体分子およびその使用
WO2017055547A1 (en) 2015-10-02 2017-04-06 Symphogen A/S Anti-pd-1 antibodies and compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CN1753912B (zh) * 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
RU2494107C2 (ru) * 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CA2920113A1 (en) * 2013-08-20 2015-02-26 Merck Sharp & Dohme Corp. Treating cancer with a combination of a pd-1 antagonist and dinaciclib
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010530753A (ja) 2007-06-18 2010-09-16 エン． フェー． オルガノン ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
JP2017506067A (ja) 2014-01-24 2017-03-02 デイナ ファーバー キャンサー インスティチュート，イ Ｐｄ−１に対する抗体分子およびその使用
WO2016014688A2 (en) 2014-07-22 2016-01-28 Junzhuan Qiu Anti-pd-1 antibodies
WO2017019846A1 (en) 2015-07-30 2017-02-02 Macrogenics, Inc. Pd-1-binding molecules and methods use thereof
WO2017055547A1 (en) 2015-10-02 2017-04-06 Symphogen A/S Anti-pd-1 antibodies and compositions

Also Published As

Publication number Publication date
JP7490109B2 (ja) 2024-05-24
US11466084B2 (en) 2022-10-11
CN110799537A (zh) 2020-02-14
EP3645740A2 (en) 2020-05-06
CN110799537B (zh) 2023-07-28
WO2019005635A2 (en) 2019-01-03
US20200157219A1 (en) 2020-05-21
JP2023107246A (ja) 2023-08-02
EP3645740A4 (en) 2021-08-18
JP2020529862A (ja) 2020-10-15

Similar Documents

Publication Publication Date Title
JP7464764B2 (ja) 抗ｒｏｒ１抗体とその作製及び使用方法
JP7490109B2 (ja) 抗ｐｄ－１抗体とその作製及び使用方法
JP7610680B2 (ja) 抗ｐｄ－ｌ１抗体とその作製及び使用方法
JP7164596B2 (ja) 抗ｃｄ３抗体とその作製及び使用方法
US20240084026A1 (en) Anti-4-1bb antibodies and methods of making and using thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220628

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220927

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221206

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230405

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20230418

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230502

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241205

R150 Certificate of patent or registration of utility model

Ref document number: 7601635

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350